• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞戈非尼治疗后转移性结直肠癌预后预测的早期形态学变化

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.

作者信息

Arai Hiroyuki, Miyakawa Kunihisa, Denda Tadamichi, Mizukami Takuro, Horie Yoshiki, Izawa Naoki, Hirakawa Mami, Ogura Takashi, Tsuda Takashi, Sunakawa Yu, Nakajima Takako Eguchi

机构信息

Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.

Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.

出版信息

Oncotarget. 2017 Nov 30;8(66):110530-110539. doi: 10.18632/oncotarget.22807. eCollection 2017 Dec 15.

DOI:10.18632/oncotarget.22807
PMID:29299166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5746401/
Abstract

BACKGROUND AND OBJECTIVE

It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib.

RESULTS

This study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). The median progression-free survival (PFS) and overall survival (OS) in patients with/without CF were 4.2/2.4 months (p<0.01) and 9.2/6.5 months (p=0.09), respectively. Among 45 patients with liver metastasis, 14 (31%) had active morphological response (MR). The median PFS and OS in patients with/without active MR were 5.3/2.4 months (p<0.01) and 13.6/6.9 months (p=0.02), respectively. Overall, 25 patients (37%) had EMC. The median PFS and OS in patients with/without EMC were 5.3/2.1 months (p<0.01) and 13.3/6.1 months (p<0.01), respectively.

MATERIALS AND METHODS

This retrospective study included mCRC patients with lung and/or liver metastases receiving regorafenib. CF in lung metastasis and MR in liver metastasis were evaluated at the first post-treatment computed tomography scan. EMC was determined as CF and/or active MR. We compared PFS and OS between patients with and those without EMC.

CONCLUSIONS

EMC could be a useful predictive marker for regorafenib in mCRC.

摘要

背景与目的

早期形态学改变（EMC）是否为转移性结直肠癌（mCRC）患者使用瑞戈非尼的预测标志物尚不清楚。因此，本研究调查了EMC能否预测接受瑞戈非尼治疗的mCRC患者的预后。

结果

本研究评估了68例患者。在52例有肺转移的患者中，16例（31%）出现空洞形成（CF）。有/无CF患者的中位无进展生存期（PFS）和总生存期（OS）分别为4.2/2.4个月（p<0.01）和9.2/6.5个月（p=0.09）。在45例有肝转移的患者中，14例（31%）出现积极的形态学反应（MR）。有/无积极MR患者的中位PFS和OS分别为5.3/2.4个月（p<0.01）和13.6/6.9个月（p=0.02）。总体而言，25例患者（37%）出现EMC。有/无EMC患者的中位PFS和OS分别为5.3/2.1个月（p<0.01）和13.3/6.1个月（p<0.01）。

材料与方法

这项回顾性研究纳入了接受瑞戈非尼治疗的有肺和/或肝转移的mCRC患者。在首次治疗后的计算机断层扫描中评估肺转移中的CF和肝转移中的MR。EMC定义为CF和/或积极的MR。我们比较了有/无EMC患者的PFS和OS。

结论

EMC可能是mCRC患者使用瑞戈非尼的有用预测标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/8321ee9182cc/oncotarget-08-110530-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/bc955350c0b3/oncotarget-08-110530-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/006f06c316e9/oncotarget-08-110530-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/b5299de04216/oncotarget-08-110530-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/ca558c0ea630/oncotarget-08-110530-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/653c40d92dc3/oncotarget-08-110530-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/8321ee9182cc/oncotarget-08-110530-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/bc955350c0b3/oncotarget-08-110530-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/006f06c316e9/oncotarget-08-110530-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/b5299de04216/oncotarget-08-110530-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/ca558c0ea630/oncotarget-08-110530-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/653c40d92dc3/oncotarget-08-110530-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab1/5746401/8321ee9182cc/oncotarget-08-110530-g006.jpg

相似文献

1
Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.瑞戈非尼治疗后转移性结直肠癌预后预测的早期形态学变化
Oncotarget. 2017 Nov 30;8(66):110530-110539. doi: 10.18632/oncotarget.22807. eCollection 2017 Dec 15.
2
3'-Deoxy-3'-F-Fluorothymidine and F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.3'-脱氧-3'-氟胸苷和 F-氟脱氧葡萄糖正电子发射断层扫描用于预测对所有标准治疗均耐药的转移性结直肠癌患者对regorafenib 的早期反应。
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1713-1722. doi: 10.1007/s00259-019-04330-7. Epub 2019 Apr 30.
3
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.二线化疗失败后 ≥ 75 岁转移性结直肠癌（mCRC）患者采用 2/1 方案应用regorafenib 的疗效和安全性。
Clin Colorectal Cancer. 2018 Dec;17(4):307-312. doi: 10.1016/j.clcc.2018.02.005. Epub 2018 Feb 21.
4
Efficacy and safety of raltitrexed plus S-1 regorafenib in patients with refractory metastatic colorectal cancer: a real-world propensity score matching study.雷替曲塞联合S-1与瑞戈非尼治疗难治性转移性结直肠癌的疗效与安全性：一项真实世界倾向评分匹配研究
Therap Adv Gastroenterol. 2022 May 18;15:17562848221098246. doi: 10.1177/17562848221098246. eCollection 2022.
5
Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study.瑞戈非尼致小肠壁水肿与转移性结直肠癌患者的瑞戈非尼不耐受和生存时间更短相关：一项回顾性研究。
J Oncol Pharm Pract. 2021 Dec;27(8):1929-1935. doi: 10.1177/1078155220978471. Epub 2020 Dec 6.
6
Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study.瑞戈非尼治疗难治性转移性结直肠癌：一项多中心回顾性研究
Front Oncol. 2022 Mar 30;12:838870. doi: 10.3389/fonc.2022.838870. eCollection 2022.
7
Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?卡培他滨联合替莫唑胺（CapTem）：作为转移性结直肠癌三线治疗方案，能否替代瑞戈非尼？
J BUON. 2019 Nov-Dec;24(6):2435-2441.
8
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).预测接受瑞戈非尼治疗的转移性结直肠癌患者临床结局的放射影像学标志物：CORRECT Ⅲ期试验的事后分析（RadioCORRECT研究）
ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.
9
Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.总病灶糖酵解（TLG）作为接受瑞戈非尼治疗的转移性结直肠癌患者的一种影像学生物标志物。
Eur J Nucl Med Mol Imaging. 2017 May;44(5):757-764. doi: 10.1007/s00259-016-3577-0. Epub 2016 Nov 25.
10
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.regorafenib 在抗血管生成初治和化疗耐药的晚期结直肠癌患者中的疗效：一项 IIb 期试验的结果。
Oncologist. 2019 Sep;24(9):1180-1187. doi: 10.1634/theoncologist.2019-0067. Epub 2019 Jun 7.

引用本文的文献

1
New response evaluation criteria using early morphological change in imatinib treatment for patients with gastrointestinal stromal tumor.采用伊马替尼治疗胃肠间质瘤患者早期形态学改变的新反应评估标准。
Gastric Cancer. 2022 Jan;25(1):218-225. doi: 10.1007/s10120-021-01234-0. Epub 2021 Aug 20.
2
Practical considerations in the use of regorafenib in metastatic colorectal cancer.瑞戈非尼用于转移性结直肠癌的实际考量
Ther Adv Med Oncol. 2020 Oct 31;12:1758835920956862. doi: 10.1177/1758835920956862. eCollection 2020.
3
Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors.

本文引用的文献

1
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.FOLFIRI 联合西妥昔单抗对比 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌（FIRE-3）：这项随机、开放标签的 3 期临床试验最终 RAS 野生型亚组中肿瘤动态的事后分析。
Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27.
2
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).贝伐珠单抗联合 FOLFIRI 和贝伐珠单抗联合 mFOLFOX6 作为转移性结直肠癌一线治疗的随机 III 期研究（WJOG4407G）。
Ann Oncol. 2016 Aug;27(8):1539-46. doi: 10.1093/annonc/mdw206. Epub 2016 May 13.
3
设计、合成及新型磺胺-1,2,3-三唑衍生物作为微管蛋白聚合抑制剂的抗增殖活性评价。
Invest New Drugs. 2018 Dec;36(6):1147-1157. doi: 10.1007/s10637-018-0632-7. Epub 2018 Jul 18.
4
Regorafenib: A Review in Metastatic Colorectal Cancer.regorafenib：转移性结直肠癌治疗的研究进展。
Drugs. 2018 Jul;78(11):1133-1144. doi: 10.1007/s40265-018-0938-y.
5
Antiproliferative Phenothiazine Hybrids as Novel Apoptosis Inducers against MCF-7 Breast Cancer.具有抗增殖作用的吩噻嗪杂合体作为新型 MCF-7 乳腺癌细胞凋亡诱导剂。
Molecules. 2018 May 28;23(6):1288. doi: 10.3390/molecules23061288.
Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.瑞戈非尼抗血管生成作用在转移性结直肠癌中的临床意义
PLoS One. 2015 Dec 15;10(12):e0145004. doi: 10.1371/journal.pone.0145004. eCollection 2015.
4
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.分析循环DNA和蛋白质生物标志物以预测瑞戈非尼的临床活性并评估转移性结直肠癌患者的预后：CORRECT试验的回顾性探索性分析
Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.
5
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 联合最佳支持治疗对比安慰剂联合最佳支持治疗用于既往治疗的转移性结直肠癌亚洲患者（CONCUR）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13.
6
Regorafenib for metastatic colorectal cancer.瑞戈非尼用于治疗转移性结直肠癌。
Lancet. 2013 May 4;381(9877):1537. doi: 10.1016/S0140-6736(13)60976-9.
7
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.regorafenib 单药治疗既往治疗的转移性结直肠癌（CORRECT）：一项国际、多中心、随机、安慰剂对照、3 期临床试验。
Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
8
Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?影像学生物标志物与接受 VEGF 抑制剂治疗的患者的结局相关吗？
Clin Cancer Res. 2012 Dec 15;18(24):6588-98. doi: 10.1158/1078-0432.CCR-12-1501. Epub 2012 Oct 23.
9
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.贝伐珠单抗抗血管生成治疗非小细胞肺癌患者的瘤腔空洞。
Cancer Imaging. 2012 Jun 29;12(1):225-35. doi: 10.1102/1470-7330.2012.0027.
10
CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab.贝伐珠单抗治疗结直肠癌肝转移瘤的 CT 疗效评价及复发独立于肿瘤大小变化。
AJR Am J Roentgenol. 2011 Dec;197(6):W1060-6. doi: 10.2214/AJR.11.6459.